Exosomal miR-125b-5p derived from adipose-derived mesenchymal stem cells enhance diabetic hindlimb ischemia repair via targeting alkaline ceramidase 2

Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-deriv...

Full description

Saved in:
Bibliographic Details
Published inJournal of nanobiotechnology Vol. 21; no. 1; pp. 189 - 18
Main Authors Guo, Jiahe, Yang, Xiaofan, Chen, Jing, Wang, Cheng, Sun, Yue, Yan, Chengqi, Ren, Sen, Xiong, Hewei, Xiang, Kaituo, Zhang, Maojie, Li, Chengcheng, Jiang, Guoyong, Xiang, Xuejiao, Wan, Gui, Jiang, Tao, Kang, Yu, Xu, Xiang, Chen, Zhenbing, Li, Wenqing
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 12.06.2023
BioMed Central
BMC
Subjects
Adipose-derived mesenchymal stem cells
Alkaline Ceramidase
Alkaline ceramidase 2
Amputation
Analysis
Angiogenesis
Animals
Bioinformatics
Bioinformatics analysis
Care and treatment
Cell culture
Cell migration
Cell proliferation
Ceramidase
Complications and side effects
Computational biology
Diabetes
Diabetes Mellitus
Diabetes therapy
Diagnosis
Doppler effect
Exosomes
Hindlimb
Hindlimb ischemia
Hypoxia
Injuries
Injury analysis
Ischemia
Limbs
Mesenchymal Stem Cells
MicroRNA
MicroRNAs
miR-125b-5p
miRNA
Morphology
Muscles
Sequences
Skeletal muscle
Stem cells
Ultracentrifugation
Wound healing
China
Bioinformatics analysis
miR-125b-5p
Adipose-derived mesenchymal stem cells
Alkaline ceramidase 2
Hindlimb ischemia
Exosomes
Online AccessGet full text

Cover

Abstract Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear. Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay. ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression. The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.
AbstractList Introduction Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear. Methods Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay. Results ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression. Conclusion The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia. Keywords: Adipose-derived mesenchymal stem cells, Exosomes, miR-125b-5p, Hindlimb ischemia, Alkaline ceramidase 2, Bioinformatics analysis
Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear.INTRODUCTIONIschemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear.Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay.METHODSExosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay.ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression.RESULTSADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression.The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.CONCLUSIONThe findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.
IntroductionIschemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear.MethodsExosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay.ResultsADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression.ConclusionThe findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.
Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear. Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay. ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression. The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.
ADSC-Exos have the potential to facilitate muscle repair in the context of diabetes. miR-125b-5p derived from ADSC-Exos played a crucial role in muscle injury. The primary biological function of miR-125b-5p is achieved by targeting ACER2. The AMPK signaling pathway may play a significant role in diabetic hindlimb ischemia.
Abstract Introduction Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear. Methods Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay. Results ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression. Conclusion The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.
Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs) derived exosomes have aroused broad attention as a cell-free treatment for ischemic diseases. However, the efficacy of exosomes from adipose-derived mesenchymal stem cells (ADSC-Exos) in treating diabetic lower limb ischemic injury remains unclear. Exosomes were isolated from ADSCs culture supernatants by differential ultracentrifugation and their effect on C2C12 cells and HUVECs was assessed by EdU, Transwell, and in vitro tube formation assays separately. The recovery of limb function after ADSC-Exos treatment was evaluated by Laser-Doppler perfusion imaging, limb function score, and histological analysis. Subsequently, miRNA sequencing and rescue experiments were performed to figure out the responsible miRNA for the protective role of ADSC-Exos on diabetic hindlimb ischemic injury. Finally, the direct target of miRNA in C2C12 cells was confirmed by bioinformatic analysis and dual-luciferase report gene assay. ADSC-Exos have the potential to promote proliferation and migration of C2C12 cells and to promote HUVECs angiogenesis. In vivo experiments have shown that ADSC-Exos can protect ischemic skeletal muscle, promote the repair of muscle injury, and accelerate vascular regeneration. Combined with bioinformatics analysis, miR-125b-5p may be a key molecule in this process. Transfer of miR-125b-5p into C2C12 cells was able to promote cell proliferation and migration by suppressing ACER2 overexpression. The findings revealed that miR-125b-5p derived from ADSC-Exos may play a critical role in ischemic muscle reparation by targeting ACER2. In conclusion, our study may provide new insights into the potential of ADSC-Exos as a treatment option for diabetic lower limb ischemia.
ArticleNumber 189
Audience Academic
Author Sun, Yue
Li, Wenqing
Xiang, Xuejiao
Yan, Chengqi
Ren, Sen
Yang, Xiaofan
Zhang, Maojie
Chen, Zhenbing
Wan, Gui
Guo, Jiahe
Li, Chengcheng
Kang, Yu
Jiang, Guoyong
Wang, Cheng
Xiong, Hewei
Jiang, Tao
Xiang, Kaituo
Xu, Xiang
Chen, Jing
Author_xml – sequence: 1
  givenname: Jiahe
  surname: Guo
  fullname: Guo, Jiahe
– sequence: 2
  givenname: Xiaofan
  surname: Yang
  fullname: Yang, Xiaofan
– sequence: 3
  givenname: Jing
  surname: Chen
  fullname: Chen, Jing
– sequence: 4
  givenname: Cheng
  surname: Wang
  fullname: Wang, Cheng
– sequence: 5
  givenname: Yue
  surname: Sun
  fullname: Sun, Yue
– sequence: 6
  givenname: Chengqi
  surname: Yan
  fullname: Yan, Chengqi
– sequence: 7
  givenname: Sen
  surname: Ren
  fullname: Ren, Sen
– sequence: 8
  givenname: Hewei
  surname: Xiong
  fullname: Xiong, Hewei
– sequence: 9
  givenname: Kaituo
  surname: Xiang
  fullname: Xiang, Kaituo
– sequence: 10
  givenname: Maojie
  surname: Zhang
  fullname: Zhang, Maojie
– sequence: 11
  givenname: Chengcheng
  surname: Li
  fullname: Li, Chengcheng
– sequence: 12
  givenname: Guoyong
  surname: Jiang
  fullname: Jiang, Guoyong
– sequence: 13
  givenname: Xuejiao
  surname: Xiang
  fullname: Xiang, Xuejiao
– sequence: 14
  givenname: Gui
  surname: Wan
  fullname: Wan, Gui
– sequence: 15
  givenname: Tao
  surname: Jiang
  fullname: Jiang, Tao
– sequence: 16
  givenname: Yu
  surname: Kang
  fullname: Kang, Yu
– sequence: 17
  givenname: Xiang
  surname: Xu
  fullname: Xu, Xiang
– sequence: 18
  givenname: Zhenbing
  surname: Chen
  fullname: Chen, Zhenbing
– sequence: 19
  givenname: Wenqing
  surname: Li
  fullname: Li, Wenqing
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37308908$$D View this record in MEDLINE/PubMed
BookMark eNp9ks1u1DAUhSNURH_gBVggS2zKIsV24sRZoaoqUKkSUoG1dWNfz7gk9mBnRu2L8Lw4nRY6FUJZ2Lr-zkl8cg6LPR88FsVrRk8Yk837xHgnWEl5VVLWibqUz4oDVrdtWTEh9h7t94vDlK4p5bzm9Ytiv2orKjsqD4pf5zchhREGMrqrknHRl2JFDEa3QUNsDCMB41YhYfkwHDGh18vbWZQmHInGYUgE_RK8RmIc9Dg5TZbOm8GNPXFJL3F0QCKuwEWyydsJ4iJTfkFg-AGD85htIozOQELCXxbPLQwJX92vR8X3j-ffzj6Xl18-XZydXpZadHIqhTGNrlsNlhnW9WCt0B3ve9rTqpZd0wshGtkwVgtooGK8blFzKZG2mgPS6qi42PqaANdqFd0I8VYFcOpuEOJCQcyXGVBJ2nayspZrbuq-7voGgTFOtaU1p9Zmrw9br9W6H9Fo9FOEYcd098S7pVqEjWKUi46KJjsc3zvE8HONaVJjzi6nCx7DOikuuRCUsnr-8LdP0Ouwjj5nNVMto51s-V9qAfkGztuQX6xnU3Xaigx2jWSZOvkHlR-T_5rOnbMuz3cE73YEmZnwZlrAOiV18fVql33zOJU_cTxUMANyC-gYUopolXYTTC7MIbkhp6Pmtqtt21Vuu7pru5ql_In0wf0_ot-wqADC
CitedBy_id crossref_primary_10_1016_j_diabres_2024_111858
crossref_primary_10_4239_wjd_v15_i6_1162
crossref_primary_10_1016_j_heliyon_2023_e22802
crossref_primary_10_1152_ajpcell_00591_2023
crossref_primary_10_1016_j_jconrel_2024_05_049
crossref_primary_10_12677_acm_2024_14112938
crossref_primary_10_1007_s12015_024_10762_y
crossref_primary_10_3389_fmed_2024_1462085
crossref_primary_10_1016_j_heliyon_2024_e39251
crossref_primary_10_3390_ijms25063562
crossref_primary_10_1186_s12933_024_02405_w
crossref_primary_10_1111_bph_70002
crossref_primary_10_3390_ijms25179481
crossref_primary_10_1016_j_colsurfb_2024_114454
crossref_primary_10_1155_2023_9517826
crossref_primary_10_3390_bioengineering12010092
crossref_primary_10_1016_j_mtbio_2023_100863
crossref_primary_10_1139_cjpp_2023_0282
crossref_primary_10_12677_ACM_2024_143658
Cites_doi 10.1016/j.biopha.2023.114245
10.3390/biom13010039
10.1080/20013078.2020.1807674
10.3389/fphys.2018.00579
10.3390/ijms21030727
10.1186/s13287-021-02475-7
10.1161/01.CIR.100.10.1134
10.1016/S0140-6736(05)67700-8
10.1016/j.jvs.2016.03.421
10.1063/5.0118862
10.1016/S0140-6736(17)32401-7
10.15283/ijsc.2015.8.1.54
10.1111/cas.14453
10.1007/978-1-4939-7526-6_11
10.1161/CIRCRESAHA.115.306424
10.1016/j.cell.2009.01.002
10.1186/s13287-019-1152-x
10.1016/j.cmet.2019.09.016
10.1080/15548627.2019.1569947
10.1093/nar/gkz757
10.7554/eLife.05005
10.1126/science.aau6977
10.1161/CIRCRESAHA.116.310557
10.1080/10717544.2021.2023699
10.1038/s41418-017-0018-y
10.3390/ijms19020417
10.1155/2018/7582730
10.1186/scrt546
10.1038/cddis.2016.181
10.1161/ATVBAHA.119.313506
10.3390/antiox12010137
10.1161/ATVBAHA.122.318196
10.3390/cells11203229
10.7150/thno.54550
10.1161/CIRCRESAHA.117.310619
10.1016/j.msec.2019.01.122
10.1186/s12933-018-0671-6
10.1038/s41598-020-73604-0
10.1038/s41420-022-00909-6
10.1161/01.ATV.0000171994.89106.ca
10.1093/nar/gkt1248
10.1038/s41420-022-01260-6
10.2337/db08-0229
10.1038/s41467-019-09174-1
10.1161/ATVBAHA.117.309714
10.1016/j.cellsig.2020.109860
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7QO
7TB
7X7
7XB
88E
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB.
LK8
M0S
M1P
M7P
P64
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12951-023-01954-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Mechanical & Transportation Engineering Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
Materials Science Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Mechanical & Transportation Engineering Abstracts
ProQuest Central Essentials
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
Materials Science Database
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Materials Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database




MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1477-3155
EndPage 18
ExternalDocumentID oai_doaj_org_article_807983ff2c2d4b49b6ea1120cf0420ff
PMC10259056
A752829681
37308908
10_1186_s12951_023_01954_8
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Fundamental Research funds for the Central Universities
  grantid: YCJJ202201037
– fundername: National Natural Science Foundation of China
  grantid: 82101473
– fundername: Shenzhen Basic Research Project
  grantid: JCYJ20210324112212034
– fundername: ;
  grantid: JCYJ20210324112212034
– fundername: ;
  grantid: YCJJ202201037
– fundername: ;
  grantid: 82101473
GroupedDBID ---
0R~
29L
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADDVE
ADMLS
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
I-F
IAO
IHR
INH
INR
ISR
ITC
ITG
ITH
KB.
KQ8
LK8
M1P
M48
M7P
MM.
M~E
O5R
O5S
OK1
OVT
P2P
PDBOC
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
RVI
SCM
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7QO
7TB
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c598t-5dd6c47caf1d19baff5c92bb0b034896b5556861145a6a31247ec288e07c2ae03
IEDL.DBID M48
ISSN 1477-3155
IngestDate Wed Aug 27 01:33:27 EDT 2025
Thu Aug 21 18:37:27 EDT 2025
Fri Jul 11 08:11:29 EDT 2025
Fri Jul 25 19:20:29 EDT 2025
Tue Jun 17 21:23:17 EDT 2025
Tue Jun 10 20:13:37 EDT 2025
Fri Jun 27 06:12:58 EDT 2025
Thu Apr 03 06:51:17 EDT 2025
Thu Apr 24 23:01:25 EDT 2025
Tue Jul 01 01:26:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Bioinformatics analysis
miR-125b-5p
Adipose-derived mesenchymal stem cells
Alkaline ceramidase 2
Hindlimb ischemia
Exosomes
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c598t-5dd6c47caf1d19baff5c92bb0b034896b5556861145a6a31247ec288e07c2ae03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/807983ff2c2d4b49b6ea1120cf0420ff
PMID 37308908
PQID 2827109872
PQPubID 44676
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_807983ff2c2d4b49b6ea1120cf0420ff
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10259056
proquest_miscellaneous_2825500140
proquest_journals_2827109872
gale_infotracmisc_A752829681
gale_infotracacademiconefile_A752829681
gale_incontextgauss_ISR_A752829681
pubmed_primary_37308908
crossref_citationtrail_10_1186_s12951_023_01954_8
crossref_primary_10_1186_s12951_023_01954_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-12
PublicationDateYYYYMMDD 2023-06-12
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-12
  day: 12
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of nanobiotechnology
PublicationTitleAlternate J Nanobiotechnology
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References S-H Chen (1954_CR14) 2022; 6
R Kalluri (1954_CR13) 2020; 367
GW Hu (1954_CR36) 2015; 6
J Pottecher (1954_CR34) 2018; 9
C Han (1954_CR23) 2019; 99
S Schiekofer (1954_CR24) 2005; 25
JH Li (1954_CR27) 2014; 42
S Ren (1954_CR15) 2022; 11
R Xu (1954_CR41) 2021; 78
T Huang (1954_CR19) 2019; 15
B Liu (1954_CR43) 2020; 111
1954_CR46
HS Joo (1954_CR20) 2020
R López-Díez (1954_CR33) 2017; 37
S Ren (1954_CR45) 2019; 10
W Jeffcoate (1954_CR4) 2017; 390
W Li (1954_CR10) 2023
DP Bartel (1954_CR18) 2009; 136
MH Yeon (1954_CR32) 2023
N Kim (1954_CR11) 2015; 8
JM Van Golde (1954_CR2) 2008; 57
1954_CR9
M Babu (1954_CR3) 2015; 117
R Yue (1954_CR22) 2022; 8
JY Cao (1954_CR38) 2021; 11
V Falanga (1954_CR29) 2005; 366
S Gorini (1954_CR30) 2018
X Zhang (1954_CR16) 2021; 12
X Zhang (1954_CR42) 2019; 30
MO Joret (1954_CR8) 2016; 64
G Li (1954_CR40) 2022
C Wang (1954_CR28) 2019
SM Grundy (1954_CR7) 1999; 100
M Babu (1954_CR6) 2023; 43
TE Whittaker (1954_CR12) 2020
R Xu (1954_CR44) 2018; 25
X Dai (1954_CR47) 2017; 120
F Figliolini (1954_CR17) 2020; 40
T Zhou (1954_CR35) 2018
C Yan (1954_CR39) 2022; 29
C Yeo (1954_CR5) 2020; 10
P Mathiyalagan (1954_CR21) 2017; 120
Y Shen (1954_CR1) 2018; 17
Y Chen (1954_CR25) 2020; 48
V Agarwal (1954_CR26) 2015; 4
Y Wang (1954_CR31) 2023; 159
J Xiao (1954_CR37) 2016; 7
References_xml – volume: 159
  year: 2023
  ident: 1954_CR31
  publication-title: Biomed Pharmacother.
  doi: 10.1016/j.biopha.2023.114245
– year: 2023
  ident: 1954_CR10
  publication-title: Biomolecules
  doi: 10.3390/biom13010039
– year: 2020
  ident: 1954_CR12
  publication-title: J Extracell Vesicles.
  doi: 10.1080/20013078.2020.1807674
– volume: 9
  start-page: 1
  year: 2018
  ident: 1954_CR34
  publication-title: Front Physiol
  doi: 10.3389/fphys.2018.00579
– year: 2020
  ident: 1954_CR20
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21030727
– volume: 12
  start-page: 1
  year: 2021
  ident: 1954_CR16
  publication-title: Stem Cell Res Ther
  doi: 10.1186/s13287-021-02475-7
– volume: 100
  start-page: 1134
  year: 1999
  ident: 1954_CR7
  publication-title: Circulation
  doi: 10.1161/01.CIR.100.10.1134
– volume: 366
  start-page: 1736
  year: 2005
  ident: 1954_CR29
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67700-8
– ident: 1954_CR9
– volume: 64
  start-page: 648
  year: 2016
  ident: 1954_CR8
  publication-title: J Vasc Surg
  doi: 10.1016/j.jvs.2016.03.421
– volume: 6
  year: 2022
  ident: 1954_CR14
  publication-title: APL Bioeng.
  doi: 10.1063/5.0118862
– volume: 390
  start-page: e29
  year: 2017
  ident: 1954_CR4
  publication-title: Lancet
  doi: 10.1016/S0140-6736(17)32401-7
– volume: 8
  start-page: 54
  year: 2015
  ident: 1954_CR11
  publication-title: Int J Stem Cells
  doi: 10.15283/ijsc.2015.8.1.54
– volume: 111
  start-page: 2259
  year: 2020
  ident: 1954_CR43
  publication-title: Cancer Sci
  doi: 10.1111/cas.14453
– ident: 1954_CR46
  doi: 10.1007/978-1-4939-7526-6_11
– volume: 117
  start-page: 289
  year: 2015
  ident: 1954_CR3
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.115.306424
– volume: 136
  start-page: 215
  year: 2009
  ident: 1954_CR18
  publication-title: Cell
  doi: 10.1016/j.cell.2009.01.002
– volume: 10
  start-page: 1
  year: 2019
  ident: 1954_CR45
  publication-title: Stem Cell Res Ther.
  doi: 10.1186/s13287-019-1152-x
– volume: 30
  start-page: 937
  year: 2019
  ident: 1954_CR42
  publication-title: Cell Metab.
  doi: 10.1016/j.cmet.2019.09.016
– volume: 15
  start-page: 1100
  year: 2019
  ident: 1954_CR19
  publication-title: Autophagy
  doi: 10.1080/15548627.2019.1569947
– volume: 48
  start-page: D127
  year: 2020
  ident: 1954_CR25
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz757
– volume: 4
  start-page: 1
  year: 2015
  ident: 1954_CR26
  publication-title: Elife
  doi: 10.7554/eLife.05005
– volume: 367
  start-page: 139
  year: 2020
  ident: 1954_CR13
  publication-title: Science (80-).
  doi: 10.1126/science.aau6977
– volume: 120
  start-page: 1466
  year: 2017
  ident: 1954_CR21
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.116.310557
– volume: 29
  start-page: 214
  year: 2022
  ident: 1954_CR39
  publication-title: Drug Deliv
  doi: 10.1080/10717544.2021.2023699
– volume: 25
  start-page: 841
  year: 2018
  ident: 1954_CR44
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-017-0018-y
– year: 2018
  ident: 1954_CR35
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19020417
– year: 2018
  ident: 1954_CR30
  publication-title: Oxid Med Cell Longev.
  doi: 10.1155/2018/7582730
– volume: 6
  start-page: 1
  year: 2015
  ident: 1954_CR36
  publication-title: Stem Cell Res Ther
  doi: 10.1186/scrt546
– volume: 7
  start-page: 1
  year: 2016
  ident: 1954_CR37
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2016.181
– volume: 40
  start-page: 239
  year: 2020
  ident: 1954_CR17
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.119.313506
– year: 2023
  ident: 1954_CR32
  publication-title: Antioxidants
  doi: 10.3390/antiox12010137
– volume: 43
  start-page: e46
  year: 2023
  ident: 1954_CR6
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.122.318196
– volume: 11
  start-page: 1
  year: 2022
  ident: 1954_CR15
  publication-title: Cells
  doi: 10.3390/cells11203229
– volume: 11
  start-page: 5248
  year: 2021
  ident: 1954_CR38
  publication-title: Theranostics
  doi: 10.7150/thno.54550
– volume: 120
  start-page: 1
  year: 2017
  ident: 1954_CR47
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.117.310619
– volume: 99
  start-page: 322
  year: 2019
  ident: 1954_CR23
  publication-title: Mater Sci Eng C
  doi: 10.1016/j.msec.2019.01.122
– volume: 17
  start-page: 1
  year: 2018
  ident: 1954_CR1
  publication-title: Cardiovasc Diabetol BioMed Central
  doi: 10.1186/s12933-018-0671-6
– volume: 10
  start-page: 1
  year: 2020
  ident: 1954_CR5
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-73604-0
– volume: 8
  start-page: 1
  year: 2022
  ident: 1954_CR22
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-022-00909-6
– volume: 25
  start-page: 1603
  year: 2005
  ident: 1954_CR24
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/01.ATV.0000171994.89106.ca
– volume: 42
  start-page: 92
  year: 2014
  ident: 1954_CR27
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkt1248
– year: 2022
  ident: 1954_CR40
  publication-title: Cell Death Discov.
  doi: 10.1038/s41420-022-01260-6
– volume: 57
  start-page: 2818
  year: 2008
  ident: 1954_CR2
  publication-title: Diabetes
  doi: 10.2337/db08-0229
– year: 2019
  ident: 1954_CR28
  publication-title: Nat Commun.
  doi: 10.1038/s41467-019-09174-1
– volume: 37
  start-page: 1536
  year: 2017
  ident: 1954_CR33
  publication-title: Arterioscler Thromb Vasc Biol.
  doi: 10.1161/ATVBAHA.117.309714
– volume: 78
  year: 2021
  ident: 1954_CR41
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2020.109860
SSID ssj0022424
Score 2.4380834
Snippet Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells (MSCs)...
Introduction Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells...
IntroductionIschemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal stem cells...
ADSC-Exos have the potential to facilitate muscle repair in the context of diabetes. miR-125b-5p derived from ADSC-Exos played a crucial role in muscle injury....
Abstract Introduction Ischemic diseases caused by diabetes continue to pose a major health challenge and effective treatments are in high demand. Mesenchymal...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 189
SubjectTerms Adipose-derived mesenchymal stem cells
Alkaline Ceramidase
Alkaline ceramidase 2
Amputation
Analysis
Angiogenesis
Animals
Bioinformatics
Bioinformatics analysis
Care and treatment
Cell culture
Cell migration
Cell proliferation
Ceramidase
Complications and side effects
Computational biology
Diabetes
Diabetes Mellitus
Diabetes therapy
Diagnosis
Doppler effect
Exosomes
Hindlimb
Hindlimb ischemia
Hypoxia
Injuries
Injury analysis
Ischemia
Limbs
Mesenchymal Stem Cells
MicroRNA
MicroRNAs
miR-125b-5p
miRNA
Morphology
Muscles
Sequences
Skeletal muscle
Stem cells
Ultracentrifugation
Wound healing
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT3BAlGegIIOQOKCoiRMn9rGgVoUDh0Kl3iw_2YhNstrsVu0f6e9lJo_VRkhw4RbF4yiZGXtmnJlvCHmvfZIGKX2sjYcAJddwZUUS50Yw7I4EFrDP8v1WnF_mX6_41V6rL8wJG-CBB8Ydi6SUIguBWeZyk0tTeA0-QmIDqFsSAu6-YPOmYGoMtbDoYSqREcVxB1aNQ9jMMHdI8jwWMzPUo_X_uSfvGaV5wuSeBTp7RB6OriM9GV75kNzzzWPyYA9Q8Am5O71pu7YGqrq6iMGrMDFfUQej195RLCWh2lWrtvPxdLPG8iO7uMVJCOpM8Si_o75ZoD7Q4Wy2snQBwfuyqg2tIB72daXpGixZtabXcDnkk8MrUL38pdFzhcesdV05MJKUPSWXZ6c_Pp_HY-eF2HIpNjF3rrB5aXVIXSqNDoFbyYxJTJLlQhaGI3BZAbEU14XOwEcovWVC-KS0DMSfPSMHTdv4F4SCO2Gz1JiAPzzBG5CBBa0zn_vggxMuIukkCGVHWHLsjrFUfXgiCjUIT4HwVC88JSLycTdnNYBy_JX6E8p3R4mA2v0NUDM1qpn6l5pF5B1qh0LIjAZzcn7qbdepL98v1EnJ8Xd0IdKIfBiJQgvfYPVY4gCcQJStGeXRjBLWtJ0PT0qoxj2lUzCGibOiZBF5uxvGmZgn1_h229NAyIlRc0SeDzq7--4MNnMhE-CHmGnzjDHzkaZa9Ijj4IVyCa7yy__BylfkPutXIjaAOiIHm_XWvwbPbmPe9Iv4N5eVS0c
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagXOCAeBMoyCAkDihq4sSJfUIFtSocOBQq7c3ysxuxSZbNbgV_hN_LTJLdboTUWxSPo9gznoc9_oaQd9onaZDSx9p4CFByDU9WJHFuBMPqSGAB-yzfb8XZRf51xmfjhls3plVudWKvqF1rcY_8CEIDTBsUJfu4_BVj1Sg8XR1LaNwmdxC6DFO6ytl1wIVXH7YXZURx1IFt4xA8M8wgkjyPxcQY9Zj9_2vmPdM0TZvcs0OnD8j90YGkxwPHH5JbvnlE7u3BCj4mf09-t11bA1VdncfgW5iYL6mD1ivvKF4oodpVy7bz8fZljZeQ7PwPdkJoZ4ob-h31zRylgg47tJWlcwjhF1VtaAVRsa8rTVdgz6oVvYLHIascfoHqxU-N_it8ZqXryoGppOwJuTg9-fH5LB7rL8SWS7GOuXOFzUurQ-pSaXQI3EpmTGKSLBeyMBzhywqIqLgudAaeQuktE8InpWUgBNlTctC0jX9OKDgVNkuNCXjsCT6BDCxonfncBx-ccBFJt4xQdgQnxxoZC9UHKaJQA_MUME_1zFMiIh92fZYDNMeN1J-QvztKhNXuX7SrSzWuUiWSUoosBGaZy00uTeE1OKSJDaDbkhAi8halQyFwRoOZOZd603Xqy_dzdVxyPJQuRBqR9yNRaGEMVo8XHWAmEGtrQnk4oYSVbafNWyFUo2bp1PU6iMibXTP2xGy5xrebngYCT4ydI_JskNnduDNQ6UImMB9iIs2TiZm2NNW8xx0HX5RLcJhf3PxfL8ld1q8xLPB0SA7Wq41_BZ7b2rzul-c_PlNCyg
  priority: 102
  providerName: ProQuest
Title Exosomal miR-125b-5p derived from adipose-derived mesenchymal stem cells enhance diabetic hindlimb ischemia repair via targeting alkaline ceramidase 2
URI https://www.ncbi.nlm.nih.gov/pubmed/37308908
https://www.proquest.com/docview/2827109872
https://www.proquest.com/docview/2825500140
https://pubmed.ncbi.nlm.nih.gov/PMC10259056
https://doaj.org/article/807983ff2c2d4b49b6ea1120cf0420ff
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zj9MwELb2kNDygLgJLJVBSDygQO44DwjtopYFiRUqVOqbZTv2NqJJStKudv8Iv5eZHFUjFl6qKDOOGnsm8409ByGvhHZckyTaFlKDgxIIuFLMsQPJPOyOBBawifI9j85mwZd5ON8jfbujbgLrG1077Cc1q5Zvr35dfwCFf98oPIve1WCzQnCKPYwMSsLAZvvkECxTjIr6NdieKniYCtEnztw47ojc8kHkWYLdJnfsVFPO_--P9o7VGkZU7pioyV1yp8OW9KQVhntkTxf3ye2dioMPyO_xVVmXOXDl2dQG2CHtcEVToF7qlGKuCRVptiprbfc3c8xPUotrHIRVnynu9ddUFwsUGNpu3maKLsC7X2a5pBnMqs4zQSswdVlFL-GyDTiHv0DF8qdAaAuPqUSepWBFqfeQzCbjHx_P7K41g63ChK3tME0jFcRKGDd1EymMCVXiSelIxw9YEskQK5tF4GyFIhI-gIhYK48x7cTKA_nwH5GDoiz0E0IBbyjfldLgiSjAhcR4RghfB9pok7LUIm6_EFx1dcuxfcaSN_4Li3i7jhzWkTfryJlF3mzHrNqqHf_lPsX13XJixe3mRlld8E6BOXPihPnGeMpLAxkkMtICsKqjDHz2HGMs8hKlg2NNjQKDdi7Epq755-9TfhKHeF4dMdcirzsmU8I7KNHlQMBMYBmuAefxgBOUXg3JvRDyXmc40DCylsWeRV5syTgSA-kKXW4aHvBJ0a22yONWZrfv3Yu-RdhAmgcTM6QU2aIpSQ4wNUwASz_950OfkSOv0TRs-3RMDtbVRj8HPLeWI7Ifz2P4ZZNPI3J4Oj7_Nh01eyOjRn3_AFZjSik
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOQAHxJtAAYNAHFDUxHk5B4QKtNqlpYfSSnsztmN3I3aTZbNb6B_hZ_AbmcljuxFSb71F8SSKPeP5ZuJ5EPJaGs-3aWpcqQw4KKGEK809N1ScYXckQMA6yvcwHpyEX0bRaIP87XJhMKyy04m1os5Kjf_It8E1wLBBnrAPs58udo3C09WuhUYjFvvm_Be4bNX74Wfg7xvG9naPPw3ctquAq6OUL9woy2IdJlpaP_NTJa2NdMqU8pQXhDyNVYRFuWLwEyIZywDwLzGacW68RDOYWgDvvUauA_B6uKOS0YWDh6kWXWIOj7crwNIInHWGEUtpFLq8B351j4D_kWANCvthmmu4t3eH3G4NVrrTSNhdsmGKe-TWWhnD--TP7u-yKqdANc2PXLBllBvNaAajZyajmMBCZZbPysq43c0pJj3p8Tk-hKWkKR4gVNQUY5RC2vwRzjUd50U2yaeK5uCFm2ku6RzwM5_TM7hsotjhE6ic_JBoL8Nr5nKaZwDNlD0gJ1fCmYdksygL85hQMGJ04Ctl8ZgVbJDUMitlYEJjjc145hC_Y4TQbTF07MkxEbVTxGPRME8A80TNPMEd8m71zKwpBXIp9Ufk74oSy3jXN8r5qWi1guBekvLAWqZZFqowVbGRYAB72oIu9ax1yCuUDoGFOgqMBDqVy6oSw29HYieJ8BA85r5D3rZEtoQ5aNkmVsBKYG2vHuVWjxI0ie4Pd0IoWk1WiYt955CXq2F8EqPzClMuaxpwdNFXd8ijRmZX8w4AQnjqwXrwnjT3FqY_UuTjus452L5RCgb6k8u_6wW5MTj-eiAOhof7T8lNVu83bC61RTYX86V5BlbjQj2vtyol369aN_wDkUZ_Zw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exosomal+miR-125b-5p+derived+from+adipose-derived+mesenchymal+stem+cells+enhance+diabetic+hindlimb+ischemia+repair+via+targeting+alkaline+ceramidase+2&rft.jtitle=Journal+of+nanobiotechnology&rft.au=Guo%2C+Jiahe&rft.au=Yang%2C+Xiaofan&rft.au=Chen%2C+Jing&rft.au=Wang%2C+Cheng&rft.date=2023-06-12&rft.eissn=1477-3155&rft.volume=21&rft.issue=1&rft.spage=189&rft_id=info:doi/10.1186%2Fs12951-023-01954-8&rft_id=info%3Apmid%2F37308908&rft.externalDocID=37308908
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-3155&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-3155&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-3155&client=summon